Literature DB >> 9097804

Evisceration with hydroxyapatite implant. Surgical technique and review of 31 case reports.

D A Kostick1, J V Linberg.   

Abstract

PURPOSE: To evaluate the use of hydroxyapatite (HA) as an orbital implant with evisceration.
BACKGROUND: Although several reports have documented good success with HA orbital implants and their use with enucleation, only a few reports mention HA with evisceration. These few reports are less favorable, with exposure rates as high as 67%. In contrast, the authors have had good success with evisceration and HA implants with no major complications and a low exposure rate.
METHODS: A retrospective analysis of all eviscerations with HA implant performed between January 1989 and July 1993 was completed (n = 31). Patients underwent evisceration with scleral modification, including anterior relaxing incisions and posterior sclerotomies to accommodate a large sphere without tension on the wound. Patient records were reviewed for demographic data, surgical indication, sphere size, clinical outcome, complications, and follow-up interval. The surgical technique is described.
RESULTS: All 31 patients underwent successful surgery with complications limited to exposure (6%), mild superior sulcus deficit (6%), and a conjunctival cyst (3%). No patient required further socket reconstruction, and no patient required peg placement to enhance motility. The average follow-up interval was 13.3 months.
CONCLUSIONS: The authors have had good success using HA orbital implants for evisceration without major complications. Primary evisceration with HA implantation after posterior sclerotomies is a safe and effective method for treating patients with a blind, painful eye.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9097804     DOI: 10.1016/s0161-6420(95)30833-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  [Anterior surface breakdown following evisceration : "Classic", "scleral modification", and "scleral patch techniques"].

Authors:  J W C Vijlbrief; F Hafezi; D Paridaens
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

2.  Temporary suture tarsorrhaphy at the time of orbital ball implantation.

Authors:  Lindsay A McGrath; Alan A McNab
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-01       Impact factor: 3.117

3.  A survey of satisfaction in anophthalmic patients wearing ocular prosthesis.

Authors:  Jong-Suk Song; Jaeryung Oh; Se Hyun Baek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-17       Impact factor: 3.117

4.  A comparison of implant extrusion rates and postoperative pain after evisceration with immediate or delayed implants and after enucleation with implants.

Authors:  Don Liu
Journal:  Trans Am Ophthalmol Soc       Date:  2005

5.  Four petals evisceration for atrophia bulbi.

Authors:  Molham A Elbakary
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Apr-Jun

6.  Effects and complications of placement of motility coupling post in porous polyethylene orbital implants.

Authors:  Hong-guang Cui; Rong-rong Hu; Hui-yan Li; Wei Han
Journal:  J Zhejiang Univ Sci B       Date:  2008-06       Impact factor: 3.066

7.  Standard enucleation with aluminium oxide implant (bioceramic) covered with patient's sclera.

Authors:  Gian Luigi Zigiotti; Sonia Cavarretta; Mariachiara Morara; Sang Min Nam; Stefano Ranno; Francesco Pichi; Andrea Lembo; Stefano Lupo; Paolo Nucci; Alessandro Meduri
Journal:  ScientificWorldJournal       Date:  2012-04-30

8.  Evisceration in the modern age.

Authors:  Laura T Phan; Thomas N Hwang; Timothy J McCulley
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

9.  Long-term surgical outcomes of porous polyethylene orbital implants: a review of 314 cases.

Authors:  Su-Kyung Jung; Won-Kyung Cho; Ji-Sun Paik; Suk-Woo Yang
Journal:  Br J Ophthalmol       Date:  2011-11-17       Impact factor: 4.638

10.  Risk factors for orbital implant exposure after evisceration: A case control study of 93 patients.

Authors:  Roshmi Gupta; Parvathi Hari; Bhawna Khurana; Anjali Kiran
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.